#United States #FDA #Brooklyn Park #Airiver Medical #Pulmonary Drug Coated Balloon

Airiver Medical Earns FDA Breakthrough Device Designation

Airiver Medical, a pioneering clinical stage company dedicated to advancing healthcare solutions for respiratory tract conditions, has achieved a significant milestone. The U.S. Food and Drug Administration (FDA) has granted Airiver's Pulmonary Drug Coated Balloon (DCB) the esteemed Breakthrough Device Designation. This designation aims to expedite its development, paving the way for faster patient access to a potentially game-changing treatment for central airway stenosis.

The clinical implications of this designation are profound. According to the FDA's Center for Devices and Radiological Health (CDRH), the Breakthrough Device Designation accelerates the path for technologies that display a significant impact on addressing life-threatening conditions. Airiver Medical's Pulmonary DCB promises to deliver such an impact, aspiring to surpass the efficacy of current treatment methods for central airway stenosis, a condition often associated with airway narrowing due to various medical circumstances, including prolonged intubation and lung transplant rescues.

Mitchell Erickson, the Director of Research and Development at Airiver Medical, stated, "Receiving this designation is extremely meaningful for us. It signifies that patients and healthcare providers may gain timely access to our innovative DCB technology, potentially providing safer and more effective treatment options. Currently, there is no optimal solution for recurrent airway stenosis—this technology could fill that critical gap."

First Patient Treated in Clinical Trial

In an exciting development, the initial patient has been successfully enrolled and treated in the pivotal clinical trial, overseen by Dr. Ashli O'Rourke from the Medical University of South Carolina. This trial is crucial as it will assess the safety and efficacy of Airiver's DCB across a broader population of up to 200 patients suffering from central airway stenosis. The FDA's investigational device exemption (IDE) has enabled Airiver Medical to progress with this important study, which contrasts its innovative approach against the existing standard of care, bare balloon dilation.

This groundbreaking technology combines traditional balloon dilation techniques with an advanced drug delivery system intended to provide not only immediate relief but also long-term symptom management. Utilizing a unique coating that facilitates localized delivery of the anti-cancer drug paclitaxel, Airiver's DCB aims to reduce the recurrence of stenosis while safeguarding surrounding healthy tissues further.

Dr. O'Rourke emphasizes the potential of this new technology, noting, "Central airway stenosis is a debilitating condition with few effective minimally invasive treatment options. I am thrilled to have had the opportunity to treat the first patient in what could become a transformative clinical trial."

The Need for Innovation

Central airway stenosis afflicts many patients, with an estimated 100,000 procedures performed annually in the United States alone involving tracheo-bronchial stenting or dilation. The conditions prompting such interventions often result from prolonged intubation, tracheostomy placements, infections, or post-lung transplant complications. The urgency for improved therapies is palpable, given that current options often lack longevity and patient comfort.

Airiver Medical remains committed to enhancing the standard of care for central airway stenosis and chronic rhinosinusitis, aiming not just to alleviate symptoms but to provide long-lasting solutions. If successful, this clinical trial's outcomes will underpin subsequent regulatory submissions to the FDA and lead to the commercialization of the Airiver Pulmonary DCB in the U.S.

As the healthcare community watches closely, Airiver Medical's innovations could herald a new era in respiratory treatment, offering hope and improved quality of life for countless patients. For further information about Airiver Medical and their pioneering projects, please visit Airiver Medical's Official Website.